Titration News and Research

RSS

Methadone safety: New clinical practice guideline from American Pain Society

Improved physician education and patient counseling about methadone safety and ECG monitoring to identify patients at high risk for cardiac problems will lead to safer use of the medication, according to the American Pain Society's Clinical Practice Guideline on Methadone Safety, published this week in The Journal of Pain.

26 Apr 2014

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.

15 Apr 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

ZephyrLIFE remote monitoring system released for the growing market of transitional care

Zephyr Technology is proud to announce the release of ZephyrLIFE - the world's first remote monitoring system designed specifically for the growing market of transitional care. Transitional care involves managing the continuity of health care during the transition between health care practitioners and facilities as a patient's condition and care needs change during the course of a chronic or acute illness, which ZephyrLIFE has been designed for.

6 Dec 2013

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

QRxPharma refiles MOXDUO New Drug Application with US FDA

QRxPharma Limited announced today that the Company resubmitted its MOXDUO New Drug Application. At a meeting in early October, the United States Food and Drug Administration provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.

26 Nov 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

New injection device delivers optimum treatment dose to hepatitis C patients

A new injection device, ViraferonPeg Clearclick, has launched in the UK today for hepatitis C patients to accurately titrate and self-administer their weekly dose of ViraferonPeg (peginterferon alfa-2b).

5 Oct 2013

Central BP achieves the same with less

Using central, rather than brachial, blood pressure (BP) to guide treatment decisions results in patients with hypertension being given less medication, show results from a randomized trial.

30 Sep 2013

Studies show that hTEE technology changes patient management in critical care

ImaCor Inc., the developer of the world's only hemodynamic transesophageal echocardiography technology, announced that multiple recent studies have shown that hTEE significantly changes patient management in critical care.

6 Aug 2013

Texas scientists develop new medium for cultivation of beneficial microorganisms

Texas A&M University System scientists from the departments of nutrition and food science and poultry science have developed a new medium for the cultivation of beneficial microorganisms called lactobacilli.

4 Jul 2013

$Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS$

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.

23 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Electroconvulsive therapy (ECT) is the most effective acute treatment for severe major depression. However, even with newer forms of ECT, there remains a significant risk of adverse cognitive effects, particularly memory problems.

7 May 2013

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.

14 Mar 2013

Structured hypertension care: VIPER lacks real bite

An intensive structured care program for hypertension management in primary care leads to some improvements in blood pressure control, results from the VIPER-BP trial show.

3 Dec 2012

Structured hypertension care: VIPER lacks real bite

An intensive structured care program for hypertension management in primary care leads to some improvements in blood pressure control, results from the VIPER-BP trial show.

29 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Titration News and Research

Methadone safety: New clinical practice guideline from American Pain Society

Obeticholic acid meets primary composite endpoint in Phase III study

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

ZephyrLIFE remote monitoring system released for the growing market of transitional care

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

QRxPharma refiles MOXDUO New Drug Application with US FDA

Recombinant hormone could REPLACE calcium supplements

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

New injection device delivers optimum treatment dose to hepatitis C patients

Central BP achieves the same with less

Studies show that hTEE technology changes patient management in critical care

Texas scientists develop new medium for cultivation of beneficial microorganisms

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Structured hypertension care: VIPER lacks real bite

Structured hypertension care: VIPER lacks real bite

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News